Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Munir T. et al, (2023), N Engl J Med

Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases.

Pagnamenta AT. et al, (2023), Genome Med, 15

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.

O'Sullivan JM. et al, (2023), Leukemia

Special edition of the Seminars in Hematology series on Global Hematology Care.

Schuh A., (2023), Semin Hematol

Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.

Li X. et al, (2023), Value Health

Treatment delays in children and young adults with lymphoma: a report from an East Africa lymphoma cohort study.

Mawalla WF. et al, (2023), Blood Adv, 7, 4962 - 4965

Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748.

Alaggio R. et al, (2023), Leukemia

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.

Shadman M. et al, (2023), Clin Lymphoma Myeloma Leuk, 23, 515 - 526

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Figueroa-Mora R. et al, (2023), Br J Haematol, 202, 48 - 53

Genomic Stratification of Hematological Malignancies.

Robbe P. and Schuh A., (2023), Hemasphere, 7

LIQUID BIOPSY FOR EARLY, NON‐INVASIVE DIAGNOSIS OF EBV‐POSITIVE BURKITT LYMPHOMA IN RESOURCE LIMITED SETTINGS

Chamba CC. et al, (2023), Hematological Oncology, 41, 334 - 335

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Hillmen P. et al, (2023), Lancet Oncol, 24, 535 - 552

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.

Davies AJ. et al, (2023), Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Response to the Comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors.

Siebert R. et al, (2023), Leukemia

Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).

Schuh A. et al, (2023), Br J Ophthalmol

Diagnostic validation of a portable whole slide imaging scanner for lymphoma diagnosis in resource-constrained setting: A cross-sectional study.

Mremi A. et al, (2023), J Pathol Inform, 14

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Hillmen P. et al, (2023), LANCET ONCOLOGY, 24, 535 - 552

Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care.

Cuppen E. et al, (2022), JCO Precis Oncol, 6

Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features.

Robbe P. et al, (2022), Nat Genet

A rare HIV-associated hyaline vascular multicentric castleman disease with good early response to single-agent rituximab: A case from Tanzania

Mawalla WF. et al, (2022), Human Pathology Reports, 30

Load More

1
2
3
4
5
6
7
...
»